Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abciximab vs Aspirin for Stroke Prevention Before CEA (ASTERICS)
NCT00126139Phase 3Terminated
- Sponsor
- University of Zurich
- Start
- Apr 2004
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abciximab in ischemic stroke and carotid artery stenosis (2 arms), sponsored by University of Zurich. Primary endpoint: Rate of recurrent ischemic strokes in territory of symptomatic carotid artery. Started Apr 2004; status: terminated.
02
Drugs
abciximab
03
Conditions
ischemic strokecarotid artery stenosis
Beyond the preview
Go deeper on NCT00126139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126139.